A few months after announcing the achievement of profitability, Doctolib would have, according to information from Bloomberg, accepted an implicit valuation of 3.6 billion euros during a sale of securities on the secondary market. Four years earlier, at the peak of post-Covid euphoria, the company was valued at 5.8 billion euros.
Between these two points, the operational trajectory is nevertheless solid with a recurring revenue base exceeding 400 million euros, a rapid reduction in losses, an upscaling of the product, and structured development in Europe, particularly in Germany.
2022/2026: a change in regime more than a correction of trajectory
In 2022, Doctolib’s valuation is part of a particular momentum, during which capital is abundant, interest rates close to zero, and the pandemic has brutally accelerated the adoption of digital tools in health. Doctolib is then seen as much more than an appointment-making tool. It becomes an almost universal entry point into the healthcare system, a de facto standard for the organization of patient flows, and, during vaccination, a critical national infrastructure.
The valuation of 5.8 billion euros reflected this projection: that of a player capable of capturing a significant part of the care value chain.
In 2026, the analytical framework has changed, the cost of capital has been reassessed, discounting models have become more conservative, and investors now demand credible profitability trajectories. Growth does not disappear as a criterion, but ceases to be sufficient.
The compression of multiples: a more structuring mechanism than growth
While Doctolib significantly increased its revenue between 2022 and 2026, at the same time, the valuation multiples of SaaS and HealthTech companies were divided. Where private markets accepted multiples above 20x income, they are now converging towards levels closer to public standards, often below 10x.
A price of liquidity, not a price of conquest
The valuation of 3.6 billion euros resulting from the 2026 operation must be interpreted for what it is: a transaction price on the secondary market. Unlike a primary round, where the company issues new shares in a context of competition between investors, the secondary is an over-the-counter market. It brings together sellers (historical employees, business angels, etc.) and buyers who seek to acquire capital without creating dilution.
In this type of transaction, the price is determined by an immediate liquidity constraint where sellers accept a discount to access cash. Buyers for their part demand a discount to compensate for the lack of future liquidity, lack of control and limited access to information. The result is a price that reflects a transactional equilibrium, and ultimately says nothing about optimal strategic value.
The end of “pandemic premium” and the return to more understandable growth
Especially since the 2022 valuation included an exceptional factor: the pandemic, during this period, Doctolib experienced massive adoption, driven by necessity. Teleconsultation has exploded, health professionals have quickly switched to digital tools, and States have integrated these platforms into their operational response.
This moment produced a halo effect on market expectations. When certain scenarios projected a rapid and lasting transformation of the care model, with a significant part of medical interactions switching to digital, in 2026, the reality is more measured. If teleconsultation has been established, it is more like an extension of the system. Care remains predominantly face-to-face, and digital uses are part of a hybrid model.
The strategic pivot: from access platform to production infrastructure
And paradoxically, it is when this bonus disappears that Doctolib becomes structurally more interesting. The company has initiated a profound transformation of its product, which is no longer limited to organizing access to care, but is integrated into its production.
By integrating administrative management bricks, patient flow coordination, and now artificial intelligence tools capable of assisting consultation, Doctolib seeks to become a productivity tool for healthcare professionals. The introduction of consultation assistants, capable of automatically structuring exchanges between doctor and patient, is part of this logic. The challenge is no longer simply to generate traffic, but to reduce administrative time, increase the number of patients treated, and improve the overall efficiency of the practice.
This change in positioning also transforms the nature of the income, which moves from a subscription for visibility, to a subscription for performance.
A more demanding, but more defensible economic equation
This repositioning also has direct implications on the economic model. It allows a price upgrade, but it also involves heavy investments, particularly in R&D and artificial intelligence. Doctolib devotes a significant portion of its revenues to these developments, and in a constrained capital environment, this strategy is demanding.
This is where the transition to a logic that is now central to mature SaaS companies, namely combining growth and profitability, takes place.
A change in the nature of capital
The 2026 secondary operation also reveals a transformation in the investor profile.
The entry of players like ATHOS, AP Moller Holding or Generation Investment Management marks a break with previous financing cycles. These investors are not positioned on rapid exit horizons, and their logic is that of a structural asset, registered over the long term.
This shift is consistent with the transformation of Doctolib itself. As the company moves closer to an infrastructure role, it attracts capital closer to that of utilities or industrial platforms than to that of classic venture capital.
